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Abstract
Different viral and non-viral vectors have been designed to allow the delivery of nucleic
acids in gene therapy. In general, non-viral vectors have been associated with increased
safety for in vivo use; however, issues regarding their efficacy, toxicity and stability continue
to drive further research. Thus, the aim of this study was to evaluate the potential use of the
polymerizable diacetylenic lipid 1,2-bis(10,12-tricosadiynoyl)-sn-glycero-3-phosphocholine
(DC8,9PC) as a strategy to formulate stable cationic lipopolymers in the delivery and protec-
tion of plasmid DNA. Cationic lipopolymers were prepared following two different methodol-
ogies by using DC8,9PC, 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC), and the
cationic lipids (CL) 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP), stearylamine
(SA), and myristoylcholine chloride (MCL), in a molar ratio of 1:1:0.2 (DMPC:DC8,9PC:CL).
The copolymerization methodology allowed obtaining cationic lipopolymers which were
smaller in size than those obtained by the cationic addition methodology although both tech-
niques presented high size stability over a 166-day incubation period at 4˚C. Cationic lipopo-
lymers containing DOTAP or MCL were more efficient in complexing DNA than those
containing SA. Moreover, lipopolymers containing DOTAP were found to form highly stable
complexes with DNA, able to resist serum DNAses degradation. Furthermore, neither of the
cationic lipopolymers (with or without DNA) induced red blood cell hemolysis, although met-
abolic activity determined on the L-929 and Vero cell lines was found to be dependent on
the cell line, the formulation and the presence of DNA. The high stability and DNA protection
capacity as well as the reduced toxicity determined for the cationic lipopolymer containing
DOTAP highlight the potential advantage of using lipopolymers when designing novel non-
viral carrier systems for use in in vivo gene therapy. Thus, this work represents the first
steps toward developing a cationic lipopolymer-based gene delivery system using polymer-
izable and cationic lipids.
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Introduction
Non-viral and viral vectors are used in gene therapy. This therapy has evolved as a strategy to
treat different acquired or inherited diseases in which a gene defect is responsible for the path-
ological condition. Gene therapy allows “repairing” the defective gene by the delivery of an
exogenous right copy of it [1–6]. Although the principles behind gene therapy are simple, the
delivery of such genes is still a challenge. Different viral and non-viral vectors have been
designed to allow the delivery of such genes, but the ideal vector has not been found yet [7–
12].
In the last decades, liposomes have been extensively studied as drug delivery systems [13].
These kinds of systems are very useful since they can protect and carry both lipophobic and/or
lipophilic drugs, they can be targeted to different sites in the organism, and they can reduce
drug side effects by lowering the amount of “free” drug in plasma [14–21]. Since liposomes
can also interact with DNA and protect it from enzymatic degradation, special interest has
arisen in these systems when designing a potential non-viral DNA carrier [6, 14, 22–32]. How-
ever, the stability of these delivery systems is still an important issue to be improved [7, 11, 33].
It has been discussed that polymerizable lipids can be used to enhance membrane stability,
both physically and chemically, after polymerization [34–44]. In line with this idea, formulat-
ing liposomes containing polymerizable diacetylenic lipids would allow obtaining higher sys-
tem stability after polymerization, and thus confer higher stability to the lipopolymer/DNA
complex. It has been previously reported that polymeric liposomes have little interaction
with DNA [23]. Recently, it has been shown that the mixture of the polymerizable diacetylenic
lipid 1,2-bis(10,12-tricosadiynoyl)-sn-glycero-3-phosphocholine (DC8,9PC) and the lipid
1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC) (1:1) itself has the ability to transfect
cells in vivo in mice [45] after being administered intratracheally. These results give the first
indication that lipopolymers formulated with the diacetylenic lipid DC8,9PC might be used for
in vivo DNA delivery. However, to our knowledge, there are no reports dealing with the opti-
mization of delivery systems containing polymerizable lipids to increase DNA interaction and
protection. Thus, the main aim of this study was to evaluate the potentiality of using polymer-
izable lipids in the design of new non-viral vectors for gene delivery. To this end, we evaluated
the possibility to improve the DNA interaction of the mixture between the polymerizable dia-
cetylenic lipid DC8,9PC and the lipid DMPC, by analyzing an appropriate methodology to
incorporate 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP), stearylamine (SA), or
myristoylcholine chloride (MCL), as cationic lipids (CL) into the lipopolymer, and determin-
ing the amount of cationic lipopolymer needed to associate plasmid DNA. To study the inter-
action of diacetylenic cationic lipopolymers with plasmid DNA, flow cytometry was used in
combination with the gel retardation assay. We also studied the effect of plasmid size, the Z-
potential, the effect of different media in the cationic lipopolymer/DNA interaction, the DNA
protection from serum DNAses, and the cytotoxicity of the different systems. All these charac-
terizations revealed an adequate methodology to obtain cationic lipopolymer and gave an
insight of the potentiality of this novel system as non-viral vectors for gene delivery.
Materials and methods
Materials
The polymerizable lipid DC8,9PC was from Avanti Polar Lipids Inc. and the phospholipid
DMPC from Lipoid GmbH. DOTAP and MCL were from Toronto Research Chemicals Inc.
and SA from Fluka. 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl tetrazolium bromide (MTT) was
from USB Corporation. SYBR1 Green I was from Molecular Probes, cell culture MEM/EBSS
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NEAA modified medium was from HyClone and antibiotic-antimycotic was from Gibco.
All other reagents were of analytical grade and used without further purification. Plasmids
pCH110 and pDsRed2-N1 were a generous gift from Dr. Vı´ctor Romanowski from Instituto de
Bioquı´mica y Biologı´a Molecular (IBBM), Universidad Nacional de La Plata (UNLP), Consejo
Nacional de Investigaciones Cientı´ficas y Te´cnicas (CONICET), Argentina.
Liposome preparation
Liposomes were prepared according to Bangham et al. (1965) [46]. Briefly, lipids were dis-
solved in chloroform, and the solvent was evaporated until a thin dry film was obtained. The
film was flushed with nitrogen and then suspended in distilled water, in general to a final 5
mM lipid concentration. In a typical formulation, lipids were used in a 1:1 molar ratio for
DMPC:DC8,9PC, or in a 1:1:0.2 molar ratio for DMPC:DC8,9PC:CL. Then, the suspension was
extruded at 50˚C fifteen times through 0.2-μm-pore polycarbonate membranes, using a Mini
Extruder from Avanti Polar Lipids. Two different methodologies were used to incorporate the
CL into the DMPC:DC8,9PC (1:1) formulation. One methodology (from now on called “copo-
lymerization”) included the CL mixed with the other two lipids (DMPC and DC8,9PC) being
dissolved in chloroform, as stated before. The other methodology (from now on called “cat-
ionic addition”), involved: 1) the preparation of the DMPC:DC8,9PC (1:1) lipopolymer (see
Extruded Vesicle Polymerization); 2) lyophilization from a frozen suspension (-80˚C overnight)
in a Freezone 4.5, LABCONCO lyophilizer (Kansas City, MO, USA), pre-cooled at -50˚C
maintaining the lyophilization process pressure within the range of 33x10-3 to 65x10-3 mbar
for 24 h; 3) the dissolution of the lyophilized powder in chloroform; 4) the addition of a CL
solution (prepared in chloroform) to obtain the final DMPC:DC8,9PC:CL 1:1:0.2 molar ratio;
5) the evaporation of the solvent until a thin dry film was obtained; 6) and finally, the film sus-
pension in distilled water to obtain a final 5 mM lipid concentration.
Extruded vesicle polymerization
Diacetylenic vesicles were polymerized under 254 nm UV light (20 cycles of 360 mJ/cm2 each),
using a UV-Stratalinker 1800, Stratagene1. The temperature was maintained at 4˚C for 5 min
in between cycles. Spectra were recorded with a Nanodrop ND-100 spectrophotometer
(Thermo Scientific), between 400 and 700 nm at room temperature [34, 47–49].
Size measurements
The size of both the vesicles and complexes was determined at 25˚C by measuring the autocor-
relation function at a 90˚ scattering angle in a 90 Plus/Bi-MAS Particle Size Analyzer (Broo-
khaven Instruments Corporation), with a light source of 632.8 nm and a 10-mW laser. Each
result is the average of three measurements and the effective diameters are reported as num-
ber-based diameters. The size stability of the cationic lipopolymers was determined for sam-
ples that were kept at 4˚C until analyzed. Samples were lightly vortexed before measurements
that were carried out on days 1 and 166 after sample preparation. Data acquisition and analysis
were conducted using the software package (Brookhaven Instruments 90Plus Particle Sizing
Software) supplied by the manufacturer.
Plasmid DNA
Plasmid DNAs pCH110 (7128 bp) and pDsRed2-N1 (4692 bp) were purified from Escherichia
coli hosts, using a Wizard1 Plus Midipreps DNA purification System from Promega, following
the instructions provided by the manufacturer. DNA concentration (absorbance at 260 nm)
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was determined with a Nanodrop ND-100 spectrophotometer. The DNA used in this work
presented absorbance at a 260/280 nm ratio higher than 1.75.
Gel retardation assay
The cationic lipopolymers and DNA were mixed in a final volume of 20 μL of sterile distilled
water and then incubated at 37˚C for 30 min. Then, 8 μL of gel loading buffer (10 mM Tris-
HCl pH 8, 2 mM EDTA, 0.01% w/v Orange G and 10% v/v glycerol) was added before loading
the sample onto an 0.8% w/v agarose gel containing ethidium bromide in a 0.1 μg/mL final
concentration. Electrophoresis was performed for 60 min in a Max horizon sub w/cast kit
comb apparatus (Amersham Biosciences), maintaining the voltage constant at 105 V with an
EC 105 power supply from E-C Apparatus Corporation, using TAE 1X (40 mM Tris, 20 mM
acetic acid, 1 mM EDTA, pH 8.0) as running buffer. Gels were viewed under a UV transillumi-
nator and images were captured with a Kodak camera using the Kodak Digital Science 1D soft-
ware. To evaluate the amount of cationic lipopolymer necessary to complex a specific amount
of plasmid DNA, as well as the effect of plasmid size, different cationic lipopolymer/plasmid
DNA ratios (expressed as mol of lipids: mol of base pairs) were evaluated (0:1, 1:1, 2:1, 3:1, 4:1,
5:1, 6:1, 8:1, 10:1, 12:1, 14:1, 16:1, 24:1, 30:1, 36:1, 42:1). These mol of lipids: mol of base pairs
ratios are equivalent to amine: phosphate ratios of 0, 0.045, 0.091, 0.136, 0.182, 0.227, 0.273,
0.364, 0.455, 0.546, 0.637, 0.728, 1.092, 1.365, 1.638, and 1.911, respectively [50–52]. In all the
ratios assayed, 1 μg of plasmid DNA was used. For the analysis, in each gel, a reference sample
of 1 μg of “free” plasmid was included and the densitometry value obtained in the quantifica-
tion of the corresponding negatively supercoiled plasmid band was set as the 100% plasmid
amount used in the experiment. Then, the values obtained for this negatively supercoiled plas-
mid band present in the other samples (incubated with lipopolymers) within the same gel were
referred to as control to calculate the percentage of complexed plasmid, with the Kodak Digital
Science 1D software. Results are the mean of at least three independent experiments and are
expressed as association percentage (100% minus the percentage of non-complexed plasmid).
Z-potential
The Z-potentials of the cationic lipopolymers were determined for a final 50 μM lipid concen-
tration in distilled water at 25˚C by phase-analysis light scattering in a Nanosizer (ZEN 3600;
Malvern Instruments, Malvern, UK) [53]. Each result is the average of three independent
measurements.
Effect of different incubation media in the cationic lipopolymer/DNA
interaction
The cationic lipopolymer/DNA complexes were formed in water, PBS (pH 7.4, 10 mM) or
MEM (HyClone, prepared as specified by the manufacturer). Complexes were prepared as
stated previously, at a 16:1 mol of lipids: mol of base pairs ratio, in the different media with
and without FBS (10% final concentration) and then incubated for additional 10 min with or
without 10% or 50% FBS. Complexes were analyzed through the Gel Retardation Assay as
described above.
Serum nucleases digestion assay
The cationic lipopolymer/DNA complexes were prepared in water, PBS and MEM as
explained in the Gel Retardation Assay section, with a 16:1 mol of lipids: mol of base pairs
ratio. After the 30-min incubation at 37˚C used to induce the formation of the complexes, FBS
Diacetylenic lipids in the design of stable lipopolymers
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was added to a final 50% v/v concentration and samples were incubated for additional 24 h at
37˚C before agarose gel electrophoresis analysis, which was performed as described in the Gel
Retardation Assay section [54].
Flow cytometry
The formation of complexes between the cationic lipopolymers and the pDsRed plasmid was
studied through flow cytometry. For each detected event, we recorded the FSC-H and SSC-H
values, as well as the fluorescence intensity in the FL1 (bandpass 530/30 nm) and FL2 (band-
pass 585/42 nm) detectors after excitation with a 488 nm wavelength from an argon-ion laser
in a FACS Calibur cytometer (BD). Data acquisition and analysis were performed using the
Cell Quest Pro software supplied by BD.
Hemolysis
The study was conducted in accordance with the principles of the Declaration of Helsinki and
was approved by the Ethics Committee of National University of Quilmes (Buenos Aires,
Argentina; ethics CE-UNQ No 2/2014). The participant (healthy donor) provided a written
informed consent to the experimental protocol before his/her study-participation.
Freshly prepared human red blood cells obtained from a healthy donor (100 μL) were incu-
bated at 37˚C with a 0.33 mM final lipid concentration, whether complexed or not with plas-
mid DNA, maintaining for all conditions the 16:1 (mol of lipids: mol of base pairs) ratio. After
4 or 24 h of incubation, samples were centrifuged at 1500X g for 10 min and supernatant
absorbance was measured at 414 nm with a Nanodrop ND-100 spectrophotometer. Hemolysis
was expressed as a percentage of the hemoglobin release induced by SDS (2% v/v) (positive
control, 100% hemolysis). Control experiments were performed measuring the supernatant
absorbance of erythrocytes incubated with PBS instead of the cationic lipopolymer [55, 56].
Viability evaluation in the L-929 and Vero cell lines
To analyze possible cytotoxic effects, cell viability was measured as the mean of the activity of
mitochondrial succinate dehydrogenase, using the tetrazolium salt MTT [57]. The L-929 and
Vero cell lines were obtained from Asociacio´n Banco Argentino de Ce´lulas (ABAC), Argen-
tina. L-929 and Vero cells were seeded in a 96-well plate at 2 x 104 cells/well density. Cells were
cultured with 150 μL MEM/EBSS NEAA (HyClone) modified medium prepared according to
the manufacturer’s instructions and supplemented with penicillin (100 U/mL), streptomycin
(100 μg/mL), amphotericin B (0.25 μg/mL) and 10% v/v FBS. The plate was incubated in a 5%
CO2 atmosphere for 24 h at 37˚C. Afterwards, at 90% cell confluence, the medium was
removed and cells were cultured in the presence of different concentrations (0.5, 1 and 1.5
mM) of polymerized DMPC:DC8,9PC:DOTAP (1:1:0.2), DMPC:DC8,9PC:SA (1:1:0.2) or
DMPC:DC8,9PC:MCL (1:1:0.2) with or without pDsRed plasmid DNA diluted in maintenance
medium (same medium as described above but supplemented with 1% FBS instead of 10%).
For all the conditions assayed, the 16:1 (mol of lipids: mol of base pairs) ratio was maintained.
After a 23-h incubation, the culture medium was removed and cells were washed twice with
PBS and incubated for 2 h in a 5% CO2 atmosphere at 37˚C with a 0.5 mg/mL MTT solution
prepared in maintenance medium [57]. Supernatants were discarded and cells were homoge-
nized with 200 μL ethanol 95% v/v. Absorbance at 595 nm was determined using a microplate
reader (MRXTC Dynex Technologies). Cells incubated only with maintenance medium were
used as a control. The absorbance obtained from this control was taken as 100% cell viability
and sample data adjusted to this value.
Diacetylenic lipids in the design of stable lipopolymers
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Statistical analysis
Results are expressed as mean ± SE. Statistical analysis was performed using Graph Pad Prism
v6.0 software. The different statistical tests used are detailed within the presented results. Dif-
ferences were considered to be significant when p< 0.05.
Results
Preparation of cationic lipopolymers
The polymerization of the DMPC:DC8,9PC 1:1 mixture has been previously described in
Alonso-Romanowski et al. (2003) and Temprana et al. (2010 and 2011) [34, 47, 49]. In these
works, the polymerization process was followed by measuring the absorbance in the visible
region after 20 polymerization cycles [34, 47, 58, 59]. Fig 1 shows the visible spectra obtained
for the DMPC:DC8,9PC:DOTAP (1:1:0.2), DMPC:DC8,9PC:SA (1:1:0.2), and DMPC:DC8,9PC:
MCL (1:1:0.2) mixtures, prepared with the copolymerization methodology after 20 irradiation
cycles.
As seen in Fig 1, the peaks observed around 480 and 520 nm are indicative of polymer for-
mation [34], whereas the absence of absorbance at λ ~ 610 nm indicates that vesicles and not
tubules were present in the suspension [34, 60].
Size measurements
Since the presence of the CL did not affect DC8,9PC polymerization in the copolymerization
methodology, the effective diameter and size stability of the cationic lipopolymer were used to
choose the best methodology for the preparation of cationic lipopolymers. Table 1 shows the
effective diameter obtained for the DMPC:DC8,9PC:DOTAP (1:1:0.2), DMPC:DC8,9PC:SA
(1:1:0.2) and DMPC:DC8,9PC:MCL (1:1:0.2) mixtures prepared with the copolymerization and
the cationic addition technique, and the size stability after a 166-day incubation at 4˚C.
Fig 1. Polymerization confirmation. Absorbance as a function of wavelength (nm) for the DMPC:DC8,9PC:
DOTAP (1:1:0.2), DMPC:DC8,9PC:MCL (1:1:0.2) and DMPC:DC8,9PC:SA (1:1:0.2) mixtures, prepared with
the copolymerization methodology, after 20 UV irradiation cycles. Peaks observed around 480 and 520 nm
are indicative of polymer formation.
https://doi.org/10.1371/journal.pone.0186194.g001
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The vesicle sizes obtained for all the formulations with the cationic addition technique
were higher than those obtained for the same formulation with the copolymerization meth-
odology (Table 1). After 166 days at 4˚C, in the case of DMPC:DC8,9PC:DOTAP (1:1:0.2),
the diameters of the cationic lipopolymers changed from 154 ± 7 nm to 106 ± 25 nm (repre-
senting a size decrease of around 31%), whereas in the case of DMPC:DC8,9PC:SA (1:1:0.2),
they changed from 157 ± 6 nm to 251 ± 3 nm (representing a size increase of around 60%)
for the copolymerized samples. No significant size change was observed for the DMPC:
DC8,9PC:MCL (1:1:0.2) sample prepared with the copolymerization methodology. On the
other hand, this sample was the only one that presented a size decrease of approximately
23% when the cationic addition methodology was used (Table 1). In light of these results,
the cationic lipopolymers made with the copolymerization methodology were used in fur-
ther experiments.
Gel retardation assay
To investigate the stoichiometry of the cationic lipopolymer/DNA complex and the effect of
plasmid size, a gel retardation assay was performed [54, 61–64]. Different cationic lipopoly-
mer/DNA ratios (mol of lipids: mol of base pairs) were evaluated maintaining constant the
amount of DNA (1 μg), both for the pCH110 and pDsRed plasmid DNAs. Fig 2a shows the
results obtained for the pCH110 plasmid and Fig 2b shows those obtained for the pDsRed
plasmid.
DMPC:DC8,9PC (1:1) did not interact with plasmid DNA since, independently of the plas-
mid (pCH110 or pDsRed) and the lipopolymer/DNA ratio used, the plasmid migrated in the
same way as the control without lipids (Fig 2). In this sense, the addition of a positive charge
through CL allowed this interaction to occur, although the association efficiency was found to
be formulation-dependent. To gain further insight in the stoichiometry of the complex, differ-
ent cationic lipopolymer/DNA ratios were tested, and the results obtained for both plasmids
were analyzed by band densitometry analysis (see Methods, section Gel Retardation Assay).
The results obtained for the different formulations and plasmids are plotted as association per-
centage versus cationic lipopolymer/DNA ratio (Fig 3).
It is important to note that the cationic lipopolymer DMPC:DC8,9PC:SA (1:1:0.2) was the
least efficient in complexing DNA when compared to DMPC:DC8,9PC:DOTAP (1:1:0.2) and
DMPC:DC8,9PC:MCL (1:1:0.2), independently of the size of the plasmid used (see Fig 3a and
3b for pCH110 plasmid and Fig 3c and 3d for pDsRed). In particular, the cationic lipopoly-
mer/pDsRed association was complete for ratios (mol of lipids: mol of base pairs) equal to or
Table 1. Light-scattering measurements.
Formulation Cationic addition Copolymerization
Day 1 (nm) Day 166 (nm) Day 1 (nm) Day 166 (nm)
DMPC:DC8,9PC:DOTAP(1:1:0.2) 565 ± 57 519 ± 13 154 ± 7 ** 106 ± 25 **
DMPC:DC8,9PC:SA(1:1:0.2) 1162 ± 274 Δ 1129 ± 103 Δ 157 ± 6 **** 251 ± 3 ****
DMPC:DC8,9PC:MCL(1:1:0.2) 611 ± 49 468 ± 15 168 ± 11 ** 182 ± 3
Cationic lipopolymer diameters, measured by light-scattering, after a 1- or 166-day incubation period at 4˚C. Values are the means of three
determinations ± standard error (SE). Statistical analysis was performed by Two-Way ANOVA with Tukey´s multiple comparisons post-test.
**<0.01;
****<0.0001 (when the same day but different methodology are compared within the same cationic lipopolymer).
Δ<0.001 (when the same day but different cationic lipopolymer are compared within the same methodology). Other values are not statistically different.
https://doi.org/10.1371/journal.pone.0186194.t001
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greater than 12:1 for DMPC:DC8.9PC:DOTAP (1:1:0.2) and DMPC:DC8.9PC:MCL (1:1:0.2)
and greater than 42:1 for DMPC:DC8.9PC:SA (1:1:0.2).
Z-potential
Since the polar head groups and the hydrophobic moieties presented differences among the
CL used and considering that this fact can have effects on the surface charges of the lipopoly-
mers, we next determined the Z-potential of the cationic lipopolymers obtained. Table 2
shows the Z-potential values obtained for the formulated cationic lipopolymers. We found no
statistical differences in the surface charge of the different cationic lipopolymer formulations.
Fig 2. Study of cationic lipopolymer/DNA interaction. Gel retardation assay for (a) DMPC:DC8,9PC:
DOTAP (1:1:0.2), DMPC:DC8,9PC:SA (1:1:0.2), DMPC:DC8,9PC:MCL (1:1:0.2) and DMPC:DC8,9PC (1:1)
mixtures incubated at 0:1, 6:1, 8:1, 10:1, 12:1, 14:1, 16:1 cationic lipopolymer or lipopolymer/pCH110 plasmid
DNA ratios (mol of lipids: mol of base pairs) and (b) DMPC:DC8,9PC:DOTAP (1:1:0.2), DMPC:DC8,9PC:SA
(1:1:0.2), DMPC:DC8,9PC:MCL (1:1:0.2) and DMPC:DC8,9PC (1:1) mixtures incubated at 0:1, 8:1, 16:1, 24:1,
30:1, 36:1, 42:1 cationic lipopolymer or lipopolymer/pDsRed plasmid DNA ratios (mol of lipids: mol of base
pairs). All lanes were loaded with 1 μg of plasmid DNA.
https://doi.org/10.1371/journal.pone.0186194.g002
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Effect of different incubation media on the cationic lipopolymer/DNA
interaction
To study the effect of the incubation media on the formation of cationic lipopolymer/DNA
complexes, the complexes (16:1 mol of lipids: mol of base pairs) were formed in water, PBS or
cell culture medium MEM, with or without FBS (10% v/v final concentration) and then incu-
bated for additional 10 min either in the presence or in the absence of 10% or 50% v/v FBS.
The results obtained are shown in Fig 4.
It is important to mention that, for comparison, the ratio used for all the formulations was
16:1 (mol of lipids: mol of base pairs ratio), although the formulation containing the CL SA, at
this ratio, could not complex all the pDsRed plasmid DNA (Fig 3d) (see “free” and/or degraded
plasmid DNA present in all lanes of the gels corresponding to the DMPC:DC8,9PC:SA (1:1:0.2)
formulation in Fig 4). Note that small amounts of serum DNAses in a short-time incubation
(10 min) turned the negatively supercoiled plasmid conformation into the relaxed form (see
Fig 3. Stoichiometry of the cationic lipopolymer/DNA complex. Percentage of plasmid DNA association
as a function of cationic lipopolymer/pCH110 (a and b) or pDsRed (c and d) plasmid DNA ratios (mol of lipids:
mol of base pairs) for the DMPC:DC8,9PC:DOTAP (1:1:0.2), DMPC:DC8,9PC:SA (1:1:0.2), and DMPC:
DC8,9PC:MCL (1:1:0.2) formulations.
https://doi.org/10.1371/journal.pone.0186194.g003
Table 2. Z-potential measurements.
Formulation Z-potential (mV)
DMPC:DC8,9PC:DOTAP(1:1:0.2) 33.3 ± 0.8
DMPC:DC8,9PC:SA(1:1:0.2) 31.8 ± 0.4
DMPC:DC8,9PC:MCL(1:1:0.2) 32.4 ± 0.6
Z-potential of cationic lipopolymers. Values are the means of three determinations ± standard error (SE).
Statistical analysis was performed by One-Way ANOVA with Tukey´s multiple comparisons post-test.
Values are not statistically different.
https://doi.org/10.1371/journal.pone.0186194.t002
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for example Fig 4, DMPC:DC8,9PC:DOTAP gel, PBS medium, lanes 1 and 2). Higher serum
DNAses activity resulted into a diffuse smear, seen in the gel lane (see for example Fig 4,
DMPC:DC8,9PC:DOTAP gel, water medium, lane 2). As seen in Fig 4, the DMPC:DC8,9PC:
DOTAP (1:1:0.2) formulation efficiently complexed the pDsRed plasmid in all the media
tested, and almost no degradation occurred after the 10-min 50% v/v serum incubation (see
lane 6, gels corresponding to the DMPC:DC8,9PC:DOTAP (1:1:0.2) formulation). This was not
the case for the DMPC:DC8,9PC:MCL (1:1:0.2) formulation, in which little DNA degradation
occurred after the 10-min 50% v/v serum incubation in all the media tested (compare Fig 4,
lane 6 of the gels corresponding to the DMPC:DC8,9PC:DOTAP (1:1:0.2) and DMPC:
DC8,9PC:MCL (1:1:0.2) formulations).
Serum nucleases digestion assay
The results obtained regarding the effect of different incubation media on the cationic lipopo-
lymer/DNA interaction suggested a good performance in protecting DNA from degradation
by the DMPC:DC8,9PC:DOTAP (1:1:0.2) formulation followed, although less efficiently, by the
DMPC:DC8,9PC:MCL (1:1:0.2) formulation. However, a 10-min incubation might not be
enough to test serum stability and protection capacity. Thus, to evaluate the cationic lipopoly-
mer/DNA stability and cationic lipopolymer protection capacity of the DMPC:DC8,9PC:
DOTAP (1:1:0.2) and DMPC:DC8,9PC:MCL (1:1:0.2) formulations, a 24-h incubation at 37˚C
in a 50% v/v FBS solution was carried out for complexes formed in water, PBS and MEM.
Fig 4. Effect of different incubation media on the cationic lipopolymer/DNA interaction. The different
cationic lipopolymers were incubated with the pDsRed plasmid DNA in a 16:1 (mol of lipids: mol of base pairs)
ratio in the medium (water, PBS or MEM) indicated on the right. Each lane was loaded with 1 μg of plasmid
DNA. Lanes correspond to: (1) pDsRed alone with an additional 10-min incubation in the indicated medium,
(2) pDsRed alone with an additional 10-min incubation in the presence of 10% v/v FBS, (3) cationic
lipopolymer (stated above the gel picture)/pDsRed plasmid DNA complex formed in the indicated medium
with an additional 10-min incubation without FBS, (4) cationic lipopolymer (stated above the gel picture)/
pDsRed plasmid DNA complex formed in the indicated medium with an additional 10-min incubation in the
presence of 10% v/v FBS, (5) cationic lipopolymer (stated above the gel picture)/pDsRed plasmid DNA
complex formed in the indicated medium with an additional 10-min incubation in the presence of 50% v/v FBS,
(6) cationic lipopolymer (stated above the gel picture)/pDsRed plasmid DNA complex formed in the indicated
medium with 10% v/v FBS and with an additional 10-min incubation in the presence of 50% v/v FBS. The two
main topological plasmid conformations, relaxed and negatively supercoiled, are indicated with arrows on the
left of the figure noted as relax and -supercoiled, respectively.
https://doi.org/10.1371/journal.pone.0186194.g004
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Results obtained for the DMPC:DC8,9PC:DOTAP (1:1:0.2) and DMPC:DC8,9PC:MCL (1:1:0.2)
formulations are shown in Fig 5.
When the pDsRed plasmid was not complexed with cationic lipopolymers, DNA was totally
degraded after the 24-h incubation in the presence of 50% v/v FBS in all the media tested (see
Fig 5, lane 2, and compare with non-degraded plasmid DNA control in lane 1). “Free” plasmid
was found in both formulations (DMPC:DC8,9PC:DOTAP (1:1:0.2) and DMPC:DC8,9PC:
MCL (1:1:0.2)) after the 24-h incubation without serum in PBS and MEM, although a higher
Fig 5. Serum nucleases digestion assay. The different cationic lipopolymers DMPC:DC8,9PC:DOTAP
(1:1:0.2) and DMPC:DC8,9PC:MCL (1:1:0.2)/pDsRed plasmid DNA complexes (16:1 mol of lipids: mol of base
pairs ratio) were formed in water, PBS or MEM (indicated on the right). Each lane was loaded with 1 μg of
plasmid DNA. Lanes correspond to: (1) pDsRed alone with a 24-h incubation in the indicated medium, (2)
pDsRed alone with a 24-h incubation in the presence of 50% v/v FBS, (3) cationic lipopolymer (stated above
the gel picture)/pDsRed plasmid DNA complex formed in the indicated medium with a 24-h incubation in the
indicated medium without FBS, and (4) cationic lipopolymer (stated above the gel picture)/pDsRed plasmid
DNA complex formed in the indicated medium with a 24-h incubation in the presence of 50% v/v FBS. The two
main topological plasmid conformations, relaxed and negatively supercoiled, are indicated with arrows on the
left of the figure noted as relax and -supercoiled, respectively. Degraded DNA is also indicated with an arrow
on the left of the figure.
https://doi.org/10.1371/journal.pone.0186194.g005
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amount of “free” plasmid was found in the latter (Fig 5, lane 3). Finally, total DNA degradation
was observed in the case of the DMPC:DC8,9PC:MCL (1:1:0.2) formulation, with almost no
detectable complexes present at the loading well (see Fig 5, lane 4, gels corresponding to the
DMPC:DC8,9PC:MCL (1:1:0.2) formulation). This was not the case for the DNA complexed
with the DMPC:DC8,9PC:DOTAP (1:1:0.2) formulation, in which little DNA degradation
occurred (see Fig 5, lane 4, gels corresponding to the DMPC:DC8,9PC:DOTAP (1:1:0.2)
formulation).
Flow cytometry
Flow cytometry can be used for the characterization of liposomal suspensions if the liposomes
are labeled with some type of fluorescent probe within the membrane [65–67]. In our work,
we found this approach very interesting since the developed cationic lipopolymers are fluores-
cent per se (61) and DNA can be labeled with SYBR Green. Thus, double fluorescence is indic-
ative of the presence of both the cationic lipopolymer and DNA.
So, we study the formation of complexes, with the advantage that the cationic lipopolymer/
DNA interaction is not altered by any probe within the membrane, usually used to study this
kind of complexes [68]. Non-polymerized vesicles were used to set control values of SSC-H
values (related to particle complexity), FSC-H values (related to particle size), FL1 (where
SYBR1 Green I-labeled plasmid DNA fluorescence is detected) and FL2 (where cationic lipo-
polymer fluorescence is detected). As an example, results obtained for non-polymerized
DMPC:DC8,9PC:MCL (1:1:0.2) liposomes for FSC-H versus SSC-H and FL2 versus FL1 are
shown in Fig 6a and 6b, respectively. Fig 6c shows that the SSC-H and FSC-H values found for
polymerized DMPC:DC8,9PC:MCL (1:1:0.2) samples were very similar to those obtained for
non-polymerized ones (Fig 6a). On the other hand, after polymerization, FL2 fluorescence val-
ues were increased (compare Fig 6d with Fig 6b). Since fluorescence in the FL1 channel was
also increased, this last value was used to set the negative fluorescence for this channel. SYBR1
Green I-labeled DNA was incubated with non-polymerized DMPC:DC8,9PC:MCL (1:1:0.2)
liposomes to set positive fluorescence in the FL1 channel. The results obtained for FSC-H ver-
sus SSC-H and FL2 versus FL1 are shown in Fig 6e and 6f, respectively. In this case, two popu-
lations were found when FSC-H and SSC-H were analyzed: one corresponding to liposomes
alone, presenting values similar to those found for the control (Fig 6a), and the other one with
higher FSC-H and SSC-H values, suggesting liposome/DNA complex formation presenting
heterogeneity in complexity and sizes (Fig 6e). As seen in Fig 6f, two populations were
detected: one presenting high fluorescence values in the FL1 channel (corresponding to com-
plexes containing SYBR1 Green I-labeled DNA), and the other non-fluorescent one corre-
sponding to liposomes alone.
The results obtained for FSC-H versus SSC-H and FL2 versus FL1 for the complexes
formed with DMPC:DC8,9PC:DOTAP (1:1:0.2) and SYBR
1 Green I-labeled DNA are shown
in Fig 7a and 7b respectively, whereas those obtained for FSC-H versus SSC-H and FL2 versus
FL1 for DMPC:DC8,9PC:MCL (1:1:0.2) complexed with SYBR
1 Green I-labeled DNA are
shown in Fig 7c and 7d, respectively. Both formulations presented a similar complexity
(SSC-H values) and size (FSC-H values) distribution (see Fig 7a for complexes formed with
DMPC:DC8,9PC:DOTAP (1:1:0.2) lipopolymer and Fig 7c for complexes formed with DMPC:
DC8,9PC:MCL (1:1:0.2) lipopolymer). It is important to remark that events with double posi-
tive fluorescence were found for complexes formed with both DMPC:DC8,9PC:DOTAP
(1:1:0.2) and DMPC:DC8,9PC:MCL (1:1:0.2) lipopolymers (Fig 7b and 7d, respectively), mean-
ing that the SYBR1 Green I-labeled plasmid DNA is complexed with the two cationic lipopo-
lymers used.
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Fig 6. Optimization of the study of cationic lipopolymer/DNA interaction by flow cytometry. Flow
cytometry analysis results for non-polymerized DMPC:DC8,9PC:MCL (1:1:0.2) liposomes, used to set control
values of (a) SSC-H values (related to particle complexity) versus FSC-H values (related to particle size) and (b)
FL1 values (where SYBR® Green I-labeled plasmid DNA fluorescence is detected) and FL2 values (where
cationic lipopolymer fluorescence is detected). (c) and (d) show the results for polymerized DMPC:DC8,9PC:
MCL (1:1:0.2) for SSC-H versus FSC-H and FL2 versus FL1 values respectively. (e) and (f) show the results for
non-polymerized DMPC:DC8,9PC:MCL (1:1:0.2)/SYBR® Green I-labeled pDsRed plasmid DNA complexes for
SSC-H and FSC-H values and FL2 versus FL1 values respectively.
https://doi.org/10.1371/journal.pone.0186194.g006
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To analyze this result in depth, different regions were drawn based on the SSC-H and
FSC-H values, and the FL1 and FL2 fluorescence of the events within these regions were ana-
lyzed. Fig 8 shows the results obtained for complexes formed with DMPC:DC8,9PC:DOTAP
(1:1:0.2) and SYBR1 Green I-labeled pDsRed plasmid. Note that the higher the complexity
and size values, the higher the fluorescence in the FL1 and FL2 channels (Fig 8a and 8b). Simi-
lar results were found for DMPC:DC8,9PC:MCL (1:1:0.2) and the pDsRed plasmid (data not
shown).
Hemolysis and viability evaluation in the L-929 and Vero cell lines
The first approach to evaluate the possible cytotoxic effect of the different formulations, either
complexed or not with plasmid DNA, was through the determination of the ability to induce
human red blood cell hemolysis. Hemolysis results showed no significant differences between
the three different cationic lipopolymers, either complexed or not with DNA, when compared
to a control experiment after a 4- and 24-h incubation (Table 3).
The L929 and Vero cell lines were used as models to test the toxicity of cationic lipopoly-
mers, either complexed or not with plasmid DNA. The results obtained with the L929 cell line
after incubation with the DMPC:DC8,9PC:DOTAP (1:1:0.2), DMPC:DC8,9PC:SA (1:1:0.2) and
DMPC:DC8,9PC:MCL (1:1:0.2) lipopolymers either complexed or not with the pDsRed plas-
mid DNA are shown in Fig 9a and 9b, respectively, whereas those obtained with the Vero cell
line after treatment with the DMPC:DC8,9PC:DOTAP (1:1:0.2), DMPC:DC8,9PC:SA (1:1:0.2)
and DMPC:DC8,9PC:MCL (1:1:0.2) lipopolymers are shown in Fig 9c (without DNA) and 9 d
(with DNA). As seen in Fig 9a and 9b, no important differences in cell viability were observed
Fig 7. Study of cationic lipopolymer/DNA interaction by flow cytometry. Flow cytometry analysis results
for (a) SSC-H versus FSC-H and (b) FL2 versus FL1 values for polymerized DMPC:DC8,9PC:DOTAP
(1:1:0.2)/SYBR® Green I-labeled pDsRed plasmid DNA complexes and (c) SSC-H versus FSC-H and (d) FL2
versus FL1 values for polymerized DMPC:DC8,9PC:MCL (1:1:0.2)/SYBR® Green I-labeled pDsRed plasmid
DNA complexes.
https://doi.org/10.1371/journal.pone.0186194.g007
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Fig 8. Study of cationic lipopolymer/DNA interaction by flow cytometry. Flow cytometry analysis results
for (a) SSC-H versus FSC-H and (b) FL2 versus FL1 values for polymerized DMPC:DC8,9PC:DOTAP
(1:1:0.2)/SYBR® Green I-labeled pDsRed plasmid DNA complexes. Different regions were drawn based on
SSC-H and FSC-H values (a) and the fluorescence values for FL1 and FL2 corresponding to each region are
marked in the FL2 versus FL1 graph (b) with the same borderline shown by the same style line arrow.
https://doi.org/10.1371/journal.pone.0186194.g008
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between cationic lipopolymers alone and cationic lipopolymer/DNA complexes for the
DMPC:DC8,9PC:DOTAP (1:1:0.2) and DMPC:DC8,9PC:MCL (1:1:0.2) formulations in the
L929 cell line; and around a 10% cell viability reduction was only observed for the DMPC:
DC8,9PC:MCL (1:1:0.2) formulation at the highest concentration assayed. This was not the
case for DMPC:DC8,9PC:SA (1:1:0.2) lipopolymers which affected L929 cell viability in approx-
imately 20 to 30% without DNA and in approximately 30 to 40% when complexed with plas-
mid DNA (Fig 9a and 9b). In the case of the Vero cell line, the three cationic lipopolymers
presented a cell viability reduction of approximately 20% at the lowest concentration assayed.
Increasing the total lipid concentration did not result in a higher cytotoxic effect for the
DMPC:DC8,9PC:DOTAP (1:1:0.2) and DMPC:DC8,9PC:SA (1:1:0.2) formulations (Fig 9c).
This was not the case for the DMPC:DC8,9PC:MCL (1:1:0.2) formulation, which presented a
cell viability reduction of approximately 40% at 1.5 mM total lipid concentration (Fig 9c). Plas-
mid DNA addition slightly increased the cytotoxic effect for the DMPC:DC8,9PC:DOTAP
(1:1:0.2) and DMPC:DC8,9PC:SA (1:1:0.2) formulations and slightly reduced it for the DMPC:
DC8,9PC:MCL (1:1:0.2) formulation, at the highest total lipid concentration used (Fig 9d).
Discussion
Liposome preparation and size measurements
For the DMPC:DC8,9PC (1:1) mixture, it has been previously described that, after UV irradia-
tion, conjugated polymers containing alternatively triple, single and double bonds are formed
[34, 69]. The polymer backbone presents absorbance in the visible region of the spectrum, and
the degree of membrane polymerization is related to both the magnitude and the wavelength
of visible absorbance peaks and depends on the number of polymer units electronically cou-
pled [34, 58, 59]. It has also been described that different parameters, including the polymeri-
zation process used, the lipid nature and the lipid ratios, may alter the polymerization [49, 70,
71]. Thus, the addition of different lipids to the DMPC:DC8,9PC (1:1) mixture might affect the
DC8,9PC polymerization by disturbing the cross-linking of the adjacent diacetylenic groups
[72]. The mixtures containing one of the three different CL (DMPC:DC8,9PC:DOTAP
(1:1:0.2), DMPC:DC8,9PC:SA (1:1:0.2) and DMPC:DC8,9PC:MCL (1:1:0.2)) were efficiently
polymerized when the CL were included in the formulation (copolymerization process) as
Table 3. Hemolysis percentage (% H).
Formulation % H(4 hours) % H(24 hours)
PBS 0.41 ± 0.05 2.43 ± 1.18
DMPC:DC8,9PC:DOTAP(1:1:0.2) 0.30 ± 0.08 2.53 ± 1.36
DMPC:DC8,9PC:SA(1:1:0.2) 0.43 ± 0.13 3.67 ± 0.83 **
DMPC:DC8,9PC:MCL(1:1:0.2) 0.33 ± 0.05 5.80 ± 2.29 ****
DMPC:DC8,9PC:DOTAP(1:1:0.2)/pDsRed (16:1) 0.33 ± 0.10 3.99 ± 0.88 **
DMPC:DC8,9PC:SA(1:1:0.2)/pDsRed (16:1) 0.41 ± 0.17 3.19 ± 1.65 *
DMPC:DC8,9PC:MCL(1:1:0.2)/pDsRed (16:1) 0.45 ± 0.08 4.16 ± 0.70 **
Hemolysis results after incubation periods of 4 or 24 h. Values are the means of five
determinations ± standard error (SE). Statistical analysis was performed by Two-Way ANOVA with Sidak´s
multiple comparisons post-test.
*<0.05;
**<0.01;
****<0.0001 (when different incubation times are compared within the same formulation). Other values are
not statistically different.
https://doi.org/10.1371/journal.pone.0186194.t003
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determined by visible spectroscopy. Moreover, previously, we published a detailed structural
characterization of these formulations containing CL, in which the polymerization efficiency
was determined by differential scanning calorimetry [48].
Since the polymerization was not affected by the presence of CL within the formulation, we
evaluated the size and the size stability of the cationic lipopolymers obtained with both the
copolymerization and the cationic addition techniques, to determine the best methodology to
prepare the cationic lipopolymers. As expected, the cationic addition technique led to larger
sized cationic lipopolymers when compared to those obtained by the copolymerization tech-
nique. In the latter, liposomes were extruded through a 0.2 μm pore polycarbonate membrane
and, after that, polymerized. Thus, the diameter sizes of the unilamellar vesicles obtained were
found to be less than 200 nm. On the other hand, in the addition technique, where extruded
lipopolymers were lyophilized, solubilized in chloroform with the CL, and rehydrated in water
after the solvent evaporation, multilamellar liposomes showed larger diameter sizes than those
obtained by the copolymerization technique.
It is interesting to point out that, independently of the CL used and the technique used
(copolymerization or cationic addition), no drastic changes occurred in the diameter sizes of
the cationic lipopolymers after a 166-day incubation period at 4˚C. As discussed previously in
Temprana et al. (2011) [47], polymerization of DMPC:DC8,9PC (1:1) lead to a higher system
Fig 9. Cytotoxicity determination. Cell viability percentage as a function of total lipid concentration (mM) for L929
cells incubated with cationic lipopolymers alone (a) or complexed with pDsRed plasmid DNA in a 16:1 (mol of lipids:
mol of base pairs) ratio (b); and for Vero cells incubated with cationic lipopolymers alone (c) or complexed with
pDsRed plasmid DNA in a 16:1 (mol of lipids: mol of base pairs) ratio (d). Statistical analysis was performed by Two-
Way ANOVA with Tukey´s multiple comparisons post-test. *<0.05; **<0.01; ***<0.001; ****<0.0001.
https://doi.org/10.1371/journal.pone.0186194.g009
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resistance to fusion or aggregation at a 4˚C storage condition for 30 days (the effective diame-
ter changed approximately 47%) when compared to the same non-polymerized formulation.
In line with this idea, we suggest that CL addition helps to improve this resistance to fusion or
aggregation at a 4˚C storage condition, although no data are available for the DMPC:DC8,9PC
(1:1) formulation in this long time period (166 days), and that this improvement might be
dependent on the CL used. In this sense, the DMPC:DC8,9PC:MCL (1:1:0.2) prepared with the
copolymerization technique presented the highest size stability after a 166-day incubation
period at 4˚C (it changed from 168 ± 11 to 182 ± 3, which represents a change of approxi-
mately 8%) among those prepared with the copolymerization technique. This observation is in
agreement with Roland et al. (2003), who described that a Z potential module greater than 25
mV is correlated with a high stability of the system [73]. In our case, the three formulations
presented Z potential values higher than 25 mV.
Gel retardation assay and Z-potential
To study the interaction between plasmid DNA and the different cationic lipopolymers, a gel
retardation assay was performed. This technique allowed demonstrating that DMPC:DC8,9PC
(1:1) does not interact with plasmid DNA. Little is known about the interaction of this kind of
lipopolymers and DNA. Chiaramoni et al. (2007) [23] described a low association percentage
of 11% (of the total amount of plasmid DNA) for the DC8,9PC:1,2-dimyristoyl-sn-glycero-
3-phosphoethanolamine (DMPE): cholesterol (2:2:1 molar ratio) mixture, although this per-
centage was determined through a technique different from that used in this work. Likewise,
the low interaction could be because lipopolymers without cationic lipids present a Z-potential
near to neutrality. Particularly, the DMPC:DC8,9PC (1:1) formulation presents a Z-potential
value of –8.73 ± 1.01 mV [74]. In this sense, we showed that addition of a CL to the DMPC:
DC8,9PC (1:1) mixture increased the plasmid DNA association efficiency to a 100%, although
the ratio needed to complex the same amount of plasmid DNA varied among the CL used.
This interaction between DMPC:DC8,9PC:CL (1:1:0.2) formulations and DNA was somehow
expected since the DNA/liposome interaction is governed mainly by electrostatic forces [6, 7,
26, 29] and our cationic lipopolymers presented Z-potential values near 30 mV. However, we
found that the formulation containing SA was less efficient in plasmid DNA complexing than
those containing DOTAP or MCL as cationic lipid, although the three of them presented no
significant differences between their Z-potential values. In a previous work, we found distinc-
tive characteristics of the membrane structure of the DMPC:DC8,9PC:SA (1:1:0.2) mixture,
when compared to those obtained for DMPC:DC8,9PC:DOTAP (1:1:0.2) and DMPC:DC8,9PC:
MCL (1:1:0.2) [48]. The correlation between the membrane structure of these cationic lipopo-
lymers and the plasmid association efficiency is beyond the present discussion, but represents
an important issue to be studied and discussed, since it should give important information at
the moment of designing new formulations involving the polymerizable lipid DC8,9PC.
Effect of different incubation media on the cationic lipopolymer/DNA
interaction and serum nucleases digestion assay
DMPC:DC8,9PC:DOTAP (1:1:0.2) and DMPC:DC8,9PC:MCL (1:1:0.2) were the most efficient
in complexing the plasmid DNA, requiring lesser amounts of lipid to obtain higher DNA asso-
ciation. As serum-containing media might induce DNA degradation by serum nucleases,
affecting plasmid integrity, which is a key issue when evaluating possible systems for gene
delivery, we studied the complexing and protecting performance of these formulations in dif-
ferent media, with and without serum. The DMPC:DC8,9PC:DOTAP (1:1:0.2) formulation
was able to efficiently complex the pDsRed plasmid in all the media tested, and almost no
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degradation occurred after the 10-min 50% v/v serum incubation. Interestingly, this protective
effect was also observed after 24-h incubation, with little DNA degradation. This was not the
case for the DMPC:DC8,9PC:MCL (1:1:0.2) formulation, in which little DNA degradation
occurred after the 10-min 50% v/v serum incubation in all the media tested, but total DNA
degradation was observed after 24 h, with almost no detectable complexes in all the media
tested.
All previously mentioned results suggest that the DMPC:DC8.9PC:SA (1:1:0.2) formulation
was the least stable and the one with less ability to complex DNA. The DMPC:DC8.9PC:MCL
(1:1:0.2) formulation showed a better performance, although it was less stable and less effective
to protect plasmid DNA than DMPC:DC8.9PC:DOTAP (1:1:0.2). This latter formulation was
able to protect almost all (depending on the incubation medium) of the plasmid DNA, even
against an incubation with 50% v/v FBS for a long time period (24 h at 37˚C), proving to be a
system with good resistance to serum DNAses. These results are in agreement with those of
Moret et al. (2001) [75], in which the DOTAP-DNA complex was stable in the presence of
DNAse I and in the presence of mouse, rat or human serum.
Flow cytometry
An interesting approach was to study the cationic lipopolymer/DNA interaction by flow
cytometry. This approach has the advantage that the interaction is not altered by any probe
within the membrane, due to the intrinsic fluorescence of the lipopolymers. Based on the less
efficiency observed for the DMPC:DC8,9PC:SA (1:1:0.2) formulation in the interaction with
DNA, only DMPC:DC8.9PC:DOTAP (1:1:0.2) and DMPC:DC8,9PC:MCL (1:1:0.2) were ana-
lyzed by flow cytometry. As expected, the cationic lipopolymers alone had a poorly complex
population, a relatively conserved size and fluorescence recorded in FL2. When both cationic
lipopolymers were incubated with the plasmid DNA pDsRed (either labeled or not), a popula-
tion with greater complexity and sizes was observed. This allowed confirming that cationic
lipopolymers interact with the plasmid pDsRed. The linear fluorescence tendency observed in
cationic lipopolymer and DNA complexes suggests that a certain conserved ratio exists and is
independent of the final complex size. These results are in agreement with those reviewed by
Majzoub et al. (2016) [76], who described the formation of different structures like lamellar
phase, inverted hexagonal phase, a hexagonal phase and a gyroid cubic phase. In these kinds of
structures, a conserved liposome/lipids/DNA ratio should be observed. Considering that poly-
merization increases membrane stability [47, 48] by forming lipopolymers within the liposome
structures [49], the best model that suits our results cannot be easily chosen. In this sense,
deeper conformational studies with cryo-electron microscopy or X-ray scattering need to be
performed to determine the structure formed by this kind of cationic lipopolymers when inter-
acting with DNA.
Hemolysis and viability evaluation in L-929 and Vero cell line
Red blood cells are among the first cells that can interact with a drug delivery system after an
intravenous inoculation. Thus, we used a model of human red blood cells to determine the
hemolytic effect of our formulations, especially when complexed with DNA. None of the for-
mulations, either complexed or not with the plasmid pDsRed, showed significant differences
when compared to the control experiment, at 4- or 24-h of incubation. Ishiwata et al. (2000)
[28] showed that liposomes containing SA usually increase the permeability of the membranes,
damaging the cells. Since our study showed no hemolytic effect for DMPC:DC8,9PC:SA
(1:1:0.2), we suggest that the lipopolymer context can reduce the effect of free SA. In line with
this idea, we have previously shown that DMPC:DC8,9PC (1:1) does not present hemolytic
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effect [47] and in this work, we demonstrated that cationic lipid addition does not increase the
ex vivo toxicity of the formulation.
However, one of the main problems associated with the use of cationic lipids is their
usual cytotoxicity [77]. Thus, the cell lines L929 and Vero were used as a model to test the
toxicity of cationic lipopolymers, either complexed or not with plasmid DNA. The cytotoxic
effect, studied as metabolic activity, was dependent on the formulation, cell line, lipid con-
centration and presence of DNA, as detailed in the results section. The DMPC:DC8,9PC:
DOTAP (1:1:0.2) formulation was the least cytotoxic. A slight tendency to increasing cyto-
toxicity was observed with the plasmid DNA addition for the DMPC:DC8.9PC:SA (1:1:0.2)
formulation. At the 16:1 ratio used, not all plasmid DNA was complexed and could lead to
the formation of large aggregates, as proposed by Kwon et al. (2008) [78]. These aggregates
could precipitate on the cells in culture, affecting their viability. However, the toxicity
observed was lower than that described by Percot et al. (2004) [62] for liposomes composed
of a cationic cholesterol derivative and DOPE, which at a concentration of 100 μM reduced
the cell viability of B16 F10 cells by 40% when not complexed with DNA. Furthermore, cyto-
toxicity is dependent on the cell line used and extrapolations between different cell lines and
formulations are not convenient [79]. Moreover, as the proper doses for optimal transfection
are unknown at this time, a potential cytotoxic effect should not be underestimated at those
concentrations.
Conclusions, perspectives and future applications
As mentioned previously, the mixture of the polymerizable diacetylenic lipid DC8.9PC and
the lipid DMPC (1:1) has the ability to deliver plasmid DNA and transfect cells in mice after
being intratracheally administered. Taking into account this fact, we evaluated two method-
ologies to incorporate different cationic lipids in this polymer in order to increase the inter-
action with the nucleic acids. From the point of view of the size and stability of the system,
the best results for cationic lipid incorporation were obtained using the "copolymerization"
methodology. Furthermore, we showed that the interaction with DNA, its protection, and
cytotoxicity is dependent on the cationic lipid used within the lipopolymer. Particularly, the
DMPC:DC8.9PC:DOTAP (1:1:0.2) formulation was the most efficient in complexing and
protecting DNA, forming highly stable complexes resistant to serum DNAs and presenting
very low cytotoxicity.
We believe that these cationic lipopolymers have a great potential to be used for in vivo
applications due to their stability, their ability to protect DNA and their reduced cytotoxicity.
Furthermore, the obtained lipopolymers could be used in the context of other techniques
intended to control and improve multigene delivery as with the layer-by-layer technique
reported by Bishop et al. (2016) [80]. Moreover, it would be very interesting to evaluate the
performance of these kinds of cationic lipopolymers to interact and protect dsRNA, siRNA or
other negatively charged molecules intended to be delivered in vivo.
Whether designing a cationic lipopolymer for DNA or RNA delivery, the type of cationic
lipid, helper lipid or other variables inherent to the formulation itself must be optimized. This
optimization has to consider the particular application for which it is being designed, the cor-
rect delivery to the expected tissue and the interaction with the target cell. Also, it has to be
taken into account the final destination of the delivered molecule in that cell, as it can be the
cytoplasm or the nucleus for the delivery of RNA or DNA, respectively.
Finally, our work highlights the advantage of using cationic lipopolymers based on diacety-
lenic lipids when designing novel non-viral carriers for use in in vivo gene therapy.
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